Literature DB >> 25381815

FOXC2 promotes colorectal cancer metastasis by directly targeting MET.

Y-M Cui1, H-L Jiao1, Y-P Ye1, C-M Chen1, J-X Wang1, N Tang1, T-T Li1, J Lin1, L Qi1, P Wu1, S-Y Wang1, M-R He2, L Liang1, X-W Bian3, W-T Liao1, Y-Q Ding1.   

Abstract

Metastasis is the major cause of death in colorectal cancer (CRC). Although multiple genes have been identified to be responsible for the development of CRC, the molecular changes that enable CRC cells to undergo early local invasion and to form distant metastatic colonies still remain largely unknown. Herein, we investigated the role of Forkhead box protein C2 (FOXC2) and explored the underlying mechanisms in invasion and metastasis of CRC. We show that both high FOXC2 expression and nuclear localization of FOXC2 are significantly correlated with advanced TNM (T=primary tumor; N=regional lymph nodes; M=distant metastasis) stages. FOXC2 enhanced the invasive abilities of CRC cells in vitro and promoted local invasion and distant metastasis in an orthotopic mouse metastatic model of CRC. Microarray analysis revealed that overexpression of FOXC2 increased the proto-oncogene MET tyrosine kinase expression and activated the hepatocyte growth factor (HGF)-MET signaling pathway. Furthermore, luciferase reporter assays and chromatin immunoprecipitation assays revealed that FOXC2 directly associated with MET promoter to increase the transcriptional activity of MET. Inhibition of MET attenuates the invasive phenotype and metastatic potential of FOXC2-overexpressing CRC cells, indicating that MET is a major mediator of FOXC2-promoted metastasis. In addition, FOXC2 expression was positively correlated with MET expression in CRC tissue samples. Our findings suggest that FOXC2 has a crucial role in CRC metastasis by regulating HGF-MET signaling via inducing MET expression, highlighting FOXC2 as a potential therapeutic target for preventing or reducing metastasis in CRC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25381815     DOI: 10.1038/onc.2014.368

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

Review 1.  Tumor metastasis: molecular insights and evolving paradigms.

Authors:  Scott Valastyan; Robert A Weinberg
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

Review 2.  The Met pathway: master switch and drug target in cancer progression.

Authors:  Massimiliano Mazzone; Paolo M Comoglio
Journal:  FASEB J       Date:  2006-08       Impact factor: 5.191

3.  The forkhead transcription factor Foxc2 promotes osteoblastogenesis via up-regulation of integrin β1 expression.

Authors:  Su Jin Park; Jogeswar Gadi; Kyoung-Won Cho; Kwang Joon Kim; Se Hwa Kim; Han-Sung Jung; Sung-Kil Lim
Journal:  Bone       Date:  2011-05-25       Impact factor: 4.398

4.  c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases.

Authors:  Hiroya Takeuchi; Anton Bilchik; Sukamal Saha; Roderick Turner; David Wiese; Maki Tanaka; Christine Kuo; He-Jing Wang; Dave S B Hoon
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

5.  HOXB7 as a prognostic factor and mediator of colorectal cancer progression.

Authors:  Wen-Ting Liao; Dan Jiang; Jian Yuan; Yan-Mei Cui; Xi-Wen Shi; Cui-Min Chen; Xiu-Wu Bian; Yong-Jian Deng; Yan-Qing Ding
Journal:  Clin Cancer Res       Date:  2011-04-07       Impact factor: 12.531

6.  The clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric carcinoma.

Authors:  Jin-Liang Zhu; Yong-Xi Song; Zhen-Ning Wang; Peng Gao; Mei-Xian Wang; Yu-Lan Dong; Cheng-Zhong Xing; Hui-Mian Xu
Journal:  Histopathology       Date:  2013-04-24       Impact factor: 5.087

Review 7.  Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.

Authors:  M J Duffy; A van Dalen; C Haglund; L Hansson; E Holinski-Feder; R Klapdor; R Lamerz; P Peltomaki; C Sturgeon; O Topolcan
Journal:  Eur J Cancer       Date:  2007-05-18       Impact factor: 9.162

8.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer.

Authors:  M F Di Renzo; M Olivero; A Giacomini; H Porte; E Chastre; L Mirossay; B Nordlinger; S Bretti; S Bottardi; S Giordano
Journal:  Clin Cancer Res       Date:  1995-02       Impact factor: 12.531

9.  Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas.

Authors:  C Liu; M Park; M S Tsao
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

10.  MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality.

Authors:  Antônio Talvane Torres De Oliveira; Delcio Matos; Angela Flávia Logullo; Sandra Regina Morini DA Silva; Ricardo Artigiani Neto; Adhemar Longatto Filho; Sarhan Sydney Saad
Journal:  Anticancer Res       Date:  2009-11       Impact factor: 2.480

View more
  44 in total

Review 1.  Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective.

Authors:  Kristian M Hargadon; Travis B Goodloe; Nathaniel D Lloyd
Journal:  Cancer Metastasis Rev       Date:  2022-06-14       Impact factor: 9.264

2.  The FOXC2 Transcription Factor Promotes Melanoma Outgrowth and Regulates Expression of Genes Associated With Drug Resistance and Interferon Responsiveness.

Authors:  Kristian M Hargadon; Balázs Györffy; Elijah W Strong; Brian D Tarnai; Jefferson C Thompson; David Z Bushhouse; Coleman E Johnson; Corey J Williams
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

3.  The Molecular Basis of Metastatic Colorectal Cancer.

Authors:  Sarah F Andres; Kathy N Williams; Anil K Rustgi
Journal:  Curr Colorectal Cancer Rep       Date:  2018-03-01

4.  Super-enhancer Acquisition Drives FOXC2 Expression in Middle Ear Cholesteatoma.

Authors:  Tomomi Yamamoto-Fukuda; Naotaro Akiyama; Hiromi Kojima
Journal:  J Assoc Res Otolaryngol       Date:  2021-04-16

5.  MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.

Authors:  Chunyou Wang; Pian Liu; Heshui Wu; Pengfei Cui; Yongfeng Li; Yao Liu; Zhiqiang Liu; Shanmiao Gou
Journal:  Oncotarget       Date:  2016-03-22

Review 6.  The Emerging Roles of Forkhead Box (FOX) Proteins in Osteosarcoma.

Authors:  Wentao Zhang; Ning Duan; Tao Song; Zhong Li; Caiguo Zhang; Xun Chen
Journal:  J Cancer       Date:  2017-06-03       Impact factor: 4.207

7.  Up-Regulation of FOXC2 and FOXQ1 Is Associated with The Progression of Gastric-Type Adenocarcinoma.

Authors:  Farzad Soleimani; Mohammadreza Hajjari; Bahram Mohammad Soltani; Mehrdad Behmanesh
Journal:  Cell J       Date:  2017-05-17       Impact factor: 2.479

8.  TIMELESS contributes to the progression of breast cancer through activation of MYC.

Authors:  Limin Chi; Yujiao Zou; Ling Qin; Weifeng Ma; Yanyan Hao; Yao Tang; Rongcheng Luo; Ziqing Wu
Journal:  Breast Cancer Res       Date:  2017-05-02       Impact factor: 6.466

9.  TLE4 promotes colorectal cancer progression through activation of JNK/c-Jun signaling pathway.

Authors:  Shu-Yang Wang; Ke Gao; Dan-Ling Deng; Juan-Juan Cai; Zhi-Yuan Xiao; Liu-Qing He; Hong-Li Jiao; Ya-Ping Ye; Run-Wei Yang; Ting-Ting Li; Li Liang; Wen-Ting Liao; Yan-Qing Ding
Journal:  Oncotarget       Date:  2016-01-19

10.  FOXC2 and CLIP4 : a potential biomarker for synchronous metastasis of ≤7-cm clear cell renal cell carcinomas.

Authors:  Jinwoo Ahn; Kyung Seok Han; Jun Hyeok Heo; Duhee Bang; You Hyun Kang; Hyun A Jin; Sung Joon Hong; Ji Hyun Lee; Won Sik Ham
Journal:  Oncotarget       Date:  2016-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.